[go: up one dir, main page]

ES2061623T3 - Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. - Google Patents

Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.

Info

Publication number
ES2061623T3
ES2061623T3 ES88200366T ES88200366T ES2061623T3 ES 2061623 T3 ES2061623 T3 ES 2061623T3 ES 88200366 T ES88200366 T ES 88200366T ES 88200366 T ES88200366 T ES 88200366T ES 2061623 T3 ES2061623 T3 ES 2061623T3
Authority
ES
Spain
Prior art keywords
cellulose
pharmaceutical
antibiotic
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88200366T
Other languages
English (en)
Inventor
Margaretha Olthoff
Boer Leonardus Wilhelmus Th De
Piet Johannes Akkerboom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BROCADES PHARMA BV
Original Assignee
BROCADES PHARMA BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8197583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061623(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BROCADES PHARMA BV filed Critical BROCADES PHARMA BV
Application granted granted Critical
Publication of ES2061623T3 publication Critical patent/ES2061623T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA UN COMPRIMIDO FARMACEUTICO QUE CONTIENE UN ANTIBIOTICO DE BETA-LACTAMA ANFOTERO, UN PRODUCTO CELULOSICO QUE ES CELULOSA MICROCRISTALINA O CELULOSA MICROFINA O UNA MEZCLA DE AMBAS Y UN SEGUNDO DESINTEGRANTE QUE ES HIDROXIPROPILCELULOSA CON BAJO GRADO DE SUSTITUCION, QUE SE DESINTEGRA COMPLETAMENTE EN AGUA EN UNOS 60 SEGUNDOS. CUANDO SE INGIERE MUESTRA UNA DIODISPONIBILIDAD TAN BUENA COMO UNA SUSPENSION FARMACEUTICA DEL ANTIBIOTICO. EL COMPRIMIDO SE PRENSA A PARTIR DE UNA MEZCLA QUE CONTIENE UN N UEVO GRANULADO PREPARADO A PARTIR DE LA SUSTANCIA ANTIBIOTICA, CELULOSA MICROCRISTALINA Y/O CELULOSA MICROFINA Y AGUA. LOS CITADOS COMPRIMIDOS SE PUEDEN PREPARAR TAMBIEN USANDO OTROS DESINTEGRANTES DE COMPRIMIDOS CONOCIDOS, COMO SEGUNDO DESINTEGRANTE.
ES88200366T 1987-03-02 1988-02-26 Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. Expired - Lifetime ES2061623T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87200357 1987-03-02

Publications (1)

Publication Number Publication Date
ES2061623T3 true ES2061623T3 (es) 1994-12-16

Family

ID=8197583

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88200366T Expired - Lifetime ES2061623T3 (es) 1987-03-02 1988-02-26 Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.

Country Status (16)

Country Link
US (1) US4950484A (es)
EP (1) EP0281200B1 (es)
JP (1) JPS63301820A (es)
KR (1) KR960009182B1 (es)
CN (1) CN1036763C (es)
AU (1) AU603870B2 (es)
CA (1) CA1338467C (es)
DE (1) DE3887179T2 (es)
DK (1) DK175508B1 (es)
ES (1) ES2061623T3 (es)
FI (1) FI94214C (es)
IE (1) IE70907B1 (es)
IL (1) IL85594A (es)
NO (1) NO174996C (es)
NZ (1) NZ223711A (es)
PT (1) PT86870B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3868245D1 (de) * 1987-11-30 1992-03-12 Gist Brocades Nv Pharmazeutische zusammensetzung und verfahren zu ihrer herstellung.
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
FR2638971B1 (fr) * 1988-11-15 1993-01-08 Vacher Dominique Comprime a delitement et/ou dissolution instantane
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
US5814337A (en) * 1992-10-07 1998-09-29 Beecham Group Plc Pharmaceutical formulation
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
EP0481294B2 (de) * 1990-10-19 2001-04-11 Spirig Ag Pharmazeutische Präparate Feste, schnell-lösliche Arzneimittelzubereitung enthaltend N-Acetylcystein
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
DE4290300T1 (de) * 1991-01-30 1993-10-07 Wellcome Found Wasserdispergierbare Tabletten
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
FR2679451B1 (fr) * 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
EP0801559B1 (en) * 1995-02-08 2002-04-24 Yamanouchi Europe B.V. Process for the preparation of oral dosage-forms containing a beta-lactam antibiotic
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
ATE208618T1 (de) 1995-09-07 2001-11-15 Smithkline Beecham Corp Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
US6423341B1 (en) * 1996-02-29 2002-07-23 Fujisawa Pharmaceutical Co., Ltd. β-lactam antibiotic-containing tablet and production thereof
TWI225402B (en) 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
AT407214B (de) * 1996-03-13 2001-01-25 Biochemie Gmbh Verfahren zur herstellung von hilfsstoffefreien agglomeraten aus beta-lactamantibiotika
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
SK3999A3 (en) 1996-07-16 1999-07-12 Gist Brocades Nv 'beta'-lactam granules free of organic solvents
AU6496498A (en) * 1997-02-07 1998-08-26 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
WO1999011261A1 (en) * 1997-08-29 1999-03-11 Dsm N.V. Granules free of excipients
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
WO1999018965A1 (en) * 1997-10-10 1999-04-22 Yamanouchi Europe B.V. Oral compositions containing a cephalosporin antibiotic
CN1242705A (zh) * 1997-11-17 2000-01-26 吉斯特-布罗卡迪斯有限公司 含有棒酸盐和一种或多种赋型剂的颗粒剂
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
WO2000018370A2 (en) 1998-09-25 2000-04-06 Delsys Pharmaceutical Corporation Liquid pharmaceutical for oral delivery
US6692779B2 (en) * 1999-03-26 2004-02-17 The Pillsbury Company Food products with biocontrol preservation
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US20020006433A1 (en) * 1999-04-29 2002-01-17 Nigel P. Davidson Pharmaceutical formulations
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
GT200100039A (es) * 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1285649A1 (en) * 2001-08-23 2003-02-26 Cimex AG Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
CA2478101A1 (en) * 2002-03-06 2003-09-12 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablets
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
AU2003246791A1 (en) 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
CN1681497A (zh) * 2002-07-16 2005-10-12 兰贝克赛实验室有限公司 口服给药用的可分散片剂
WO2004014337A2 (en) * 2002-08-02 2004-02-19 Ranbaxy Laboratories Limited A process for the preparation of dispersible tablet of cephalexin
EP1720533B1 (en) * 2004-02-24 2015-03-25 Sandoz Ag Amoxicillin instant granulate
US20050244343A1 (en) * 2004-04-30 2005-11-03 Withiam Michael C Oral care products comprising silica
US20050244347A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Oral care products comprising calcium phosphates
US20070196477A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area calcium phosphates
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
JP5227591B2 (ja) * 2005-01-07 2013-07-03 サンド・アクチエンゲゼルシヤフト アモキシシリンを含む粒剤の調製方法
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
KR20100033400A (ko) * 2007-06-06 2010-03-29 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
CA2749273C (en) 2008-01-09 2018-09-04 Charleston Laboratories, Inc. Pharmaceutical oral dosage form comprising a triptan and an antiemetic
BRPI1008280A2 (pt) 2009-02-24 2015-08-25 Ritter Pharmaceuticals Inc Formulações prebióticas e métodos mde uso
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
TR200909786A1 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Sefiksim içeren efervesan tablet ve granül formülasyonu.
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
TR201010860A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Sefdinir formulasyonları için üretim yöntemi.
TR201009167A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Sefalosporin içeren farmasötik granüller.
EP2814466B1 (en) * 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
EP2882423A1 (en) 2012-08-07 2015-06-17 Sandoz AG Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide
JP6441890B2 (ja) * 2013-03-15 2018-12-19 ブレインツリー・ラボラトリーズ，インコーポレイテッド 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
WO2015163135A1 (ja) * 2014-04-21 2015-10-29 株式会社ダイセル 微小繊維状セルロースを含む崩壊性粒子組成物
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
JPS5438167B2 (es) * 1974-04-27 1979-11-19
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
JPS5620513A (en) * 1979-07-31 1981-02-26 Eisai Co Ltd Sugar-coated tablet containing fat-soluble drug
GB2058565B (en) * 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) * 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4428951A (en) * 1982-04-22 1984-01-31 Fujisawa Pharmaceutical Co., Ltd. Long acting pharmaceutical composition
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS6097919A (ja) * 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) * 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds

Also Published As

Publication number Publication date
EP0281200A1 (en) 1988-09-07
DK108888A (da) 1988-09-03
IL85594A (en) 1992-11-15
CA1338467C (en) 1996-07-23
NO174996B (no) 1994-05-09
NO174996C (no) 1994-08-17
EP0281200B1 (en) 1994-01-19
KR960009182B1 (ko) 1996-07-16
IE70907B1 (en) 1997-01-15
CN88101104A (zh) 1988-12-21
FI880928A0 (fi) 1988-02-29
NZ223711A (en) 1989-08-29
DE3887179T2 (de) 1994-06-16
AU1252088A (en) 1988-09-01
PT86870A (pt) 1988-04-01
IE880584L (en) 1988-09-02
DK108888D0 (da) 1988-03-01
FI94214B (fi) 1995-04-28
DE3887179D1 (de) 1994-03-03
AU603870B2 (en) 1990-11-29
NO880904L (no) 1988-09-05
FI880928L (fi) 1988-09-03
PT86870B (pt) 1992-05-29
NO880904D0 (no) 1988-03-01
JPS63301820A (ja) 1988-12-08
US4950484A (en) 1990-08-21
DK175508B1 (da) 2004-11-15
CN1036763C (zh) 1997-12-24
KR880010757A (ko) 1988-10-24
FI94214C (fi) 1995-08-10

Similar Documents

Publication Publication Date Title
ES2061623T3 (es) Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
Bushra et al. Formulation development and optimization of ibuprofen tablets by direct compression method
PE71699A1 (es) Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
SE8700498D0 (sv) Novel pharmaceologically active compounds
DE69928554D1 (de) Therapeutische formulierung enthaltende dosierungsform
ES2090395T3 (es) Formulados farmaceuticos gastroresistentes para administracion por via oral que contienen acidos biliares.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
ES2029776T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas que contienen bromocriptina con gran estabilidad y productos relacionados.
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
SE0200154D0 (sv) New process
ATE104548T1 (de) Tablette und granulat welche als wirkstoff mesna enthalten.
UA27954C2 (uk) Біологічно активна речовина фармацевтичної композиції для лікування гіперглікемій та фармацевтична композиція з протигіперглікемічною активністю
EP0427124A3 (en) Antacid tablets
ES2062891T3 (es) Compuestos de 1,2,3,4-oxatriazol-5-imina 3-sustituidos, un proceso para la preparacion de los mismos y un preparado farmaceutico que contiene tales compuestos.
IL82523A0 (en) Microbicidal compositions,their manufacture and drugs containing them
ES2047540T3 (es) Compuesto farmaceutico y procedimiento para su preparacion.
ES8601687A1 (es) Procedimiento para producir una tableta de administracion oral de liberacion controlada, independiente del ph
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
AR015999A1 (es) 1,2,4-triazolo (3,4-a) piridazina sustituida, composicion farmaceutica que los comprende, procedimiento para su produccion y el uso de dichos compuestospara la manufactura de un medicamento
TH30780A (th) ยาเม็ดกาแลนธามีนไฮโดรโบรไมด์ที่ละลายได้เร็ว